Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

142P - Correlating total tumor volume on CT-Scan and liquid biopsy ctDNA in 1017 patients with metastatic cancer: A novel study

Date

21 Oct 2023

Session

Poster session 01

Topics

Clinical Research;  Genetic and Genomic Testing;  Staging and Imaging

Tumour Site

Presenters

Younes Belkouchi

Citation

Annals of Oncology (2023) 34 (suppl_2): S233-S277. 10.1016/S0923-7534(23)01932-4

Authors

Y. Belkouchi1, L. Dawi2, L. LAWRANCE3, S. Ammari3, D. Vasseur4, F. Wirth2, O. Gautier2, P. Cournede3, J. Hadchiti2, C. David2, F. Bidault2, C. Balleyguier5, M. KIND6, H. talbot7, A. Italiano8, N. Lassau9

Author affiliations

  • 1 Opis Inria, CentraleSupélec - Paris-Saclay campus, 91192 - Gif sur Yvette/FR
  • 2 Imaging, Gustave Roussy, Paris/FR
  • 3 Imaging, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 4 Molecular Biology, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 5 Imaging, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 6 Imaging, Institut Bergonie, 33000 - BORDEAUX/FR
  • 7 Imaging, CentraleSupélec - Paris-Saclay campus, 91192 - Gif sur Yvette/FR
  • 8 Early Phase Trials Unit, Institute Bergonié, 33000 - Bordeaux/FR
  • 9 Val De Marne, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 142P

Background

Liquid biopsy is an emerging technology capable of detecting cancer, while CT-imaging is the gold standard. We aim to correlate imaging features from CT-scans to liquid biopsy ctDNA tumor fraction (TF) and blood Tumor Mutational Burden (bTMB).

Methods

This retrospective multicentric study included 1017 patients with metastatic cancer who underwent a variety of treatments. Liquid biopsy and contemporaneous CT-scans were collected. TF and bTMB values were computed using FoundationOne Liquid CDX solution by Roche, with high tumor fraction being over 10%. Two expert radiologists outlined all cancerous lesions in the largest axial diameter. Total tumor volume (TTV) was defined as the sum of estimated lesion volumes. Training set consisted of data from several imaging centers, while the validation set was single-center. Continuous value distributions by category were tested using the Mann-Whitney U-test, and a threshold was set with ROC curve analysis using Youden's Index. This cutoff defined high and low groups, and a Χ2 test of independence was used to examine the correlation. Sensitivity and specificity were reported with imaging features taken as the gold standard. Subanalyses were run on patients with liver lesions.

Results

Overall, 55294 lesions were annotated, most commonly located in the lung (n=20074), liver (n=11297) and lymph nodes (n=10222). The train and validation sets included 599 and 418 patients. Preliminary analyses were performed on the train set. Patients with low TF had significantly less TTV than those with high TF (p<0.001). ROC analysis yielded an AUC of 0.63 with a threshold of 106 cm3. Correlation was significant between TTV and TF categories (Χ2 test: p<0.001). The sensitivity and specificity were 76% and 42%. For patients with liver lesions (n=253) , TTV threshold was 108 cm3 with an AUC of 0.66. Correlation was significant between TTV and TF categories (Χ2 test: p<0.001). The sensitivity and specificity were 82% and 42%.

Conclusions

Analysis showed significant correlation between TTV and ctDNA TF. Sensitivity was higher for patients with liver lesions, suggesting that some organs shed tumoral DNA more than others. The study of tumor heterogeneity on imaging and its correlation to bTMB is in progress.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.